Literature DB >> 2652318

Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.

M J George1, J F Heron, P Kerbrat, J Chauvergne, A Goupil, D Lebrun, J P Guastalla, M Namer, R Bugat, Y Ayme.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2652318

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  8 in total

Review 1.  Salvage therapy for ovarian cancer.

Authors:  A A Garcia
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

3.  Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.

Authors:  Kaisa Erjala; Misa Raitanen; Jarmo Kulmala; Reidar Grénman
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-05       Impact factor: 4.553

Review 4.  Prevention and management of extravasation of cytotoxic drugs.

Authors:  G Bertelli
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 5.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  Biliary elimination and pharmacokinetics of vinorelbine in micropigs.

Authors:  D Levêque; M Merle-Melet; L Bresler; J P Didelot; J P Aymard; J Wihlm; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Plasma pharmacokinetics, tissue disposition, excretion and metabolism of vinorelbine in mice as determined by high performance liquid chromatography.

Authors:  O van Tellingen; A V Kuijpers; J H Beijnen; W J Nooijen; A Bult
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

8.  Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer.

Authors:  D Levêque; E Quoix; P Dumont; G Massard; J G Hentz; A Charloux; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.